AOD-9604 is marketed as a fat-loss fragment derived from growth hormone, positioned as lipolytic without GH side effects. What the evidence looks like: AOD-9604 has been studied in humans with a focus on safety/tolerability, including multiple randomized trials described in the literature
Additional support was provided by American Diabetes Association Basic Research Awards 7-12-BS-077 (G.G.H) and 1-12-BS-109 (C.A.L.)
View Full Study Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia
Remarkably, low dietary fiber intake reduces beneficial bacteria capable of fermenting dietary fiber to produce SCFAs
The progressive form, MASH, exhibits hepatocyte damage, inflammatory cell infiltration, and variable degrees of tissue fibrosis, with advanced fibrosis representing the predominant prognostic determinant for hepatic morbidity and mortality, as well as an additional risk factor for extrahepatic complications
This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses Because of its potency, dosing strategy is at the center of how Retatrutide works
